Investor Presentaiton
OmnImmune Acute Myeloid Leukemia Phase 1b Trial Summary
TC
BIOPHARM
Based on compelling clinical data in non-responding patients TCB has progressed to
phase 2/3 studies
AML patients, late-stage, non-responders
Poor life expectancy (often days/weeks)
Prior clinical options have failed in all patients
10
Results
Average cancer levels in bone decreased from 38%
to 6%
One patient had a complete response; another
classified MLFS* following treatment; and one
stable disease
No serious adverse treatment-related safety events.
No grade 3≥ Omnlmmune® (TCB002) treatment
related toxicities were noted
One patient died because of bilateral pneumonia
determined unrelated to study medication
*MLFS: morphologic leukemia-free stateView entire presentation